NCT02132494 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

1
Kjærnsli, M., Tid for tunge løft: norske elevers kompetanse i naturfag, lesing og matematikk i PISA 2006. 2007, Oslo: Universitetsforl.
3
WHO, World Health Organization. Prevention and control of noncommunicable diseases: implementation of the global strategy. 2008, WHO: Geneva.
4
WHO, World Health Organization [cited 2013 15.08]; Available from: http://www.euro.who.int/en/what-we-do/health-topics/disease-prevention/physical-activity/facts-and-figures/10-key-facts-on-physical-activity-in-the-who-european-region. 2011, WHO.
5
WHO, World Health Organization. Global Strategy on Diet, Physical Activity and Health. 57th World Health Assembly. 2004, WHO: Geneva.
6
PttSL, (2010-2011) Act on public health work.Lov om Folkehelsearbeid. 2010
Singh A, Uijtdewilligen L, Twisk JW, van Mechelen W, Chinapaw MJ
Physical activity and performance at school: a systematic review of the literature including a methodological quality assessment. Arch Pediatr Adolesc Med. 2012 Jan;166(1):49-55. doi: 10.1001/archpediatrics.2011.716. Review.

Active Smarter Kids: A Cluster-randomized Controlled Trial Investigating the Effect of Daily Physical Activity on Children's Academic Performance and on Risk Factors for Lifestyle-related Non-communicable Diseases

Details for clinical trial NCT02132494

Clinical trial NCT02132494 - References